Dear User, This website provides you with information only for healthcare professionals. According to the drug promotion code, we are only able to allow healthcare professionals like physicians and pharmacists to have full access to our website. To visit our page please login.

Daiichi Sankyo
Doc Check

European News

UK’s NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent deep vein thrombosis and pulmonary embolism in adults

Real World ETNA Registries of New Once-Daily LIXIANA® (edoxaban) Start in Europe

Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients

Daiichi Sankyo’s Once-Daily LIXIANA® (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE

Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer

Expert report highlights urgent action needed to lessen the future impact of Atrial Fibrillation in Europe

Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Europe

Lixiana® (edoxaban) Approved in Switzerland

Global News

Global LIXIANA® Press Portal

Cookie preferences tool